Juillerat, Pascal; Pittet, Valérie; Vader, John-Paul; Burnand, Bernard; Gonvers, Jean-Jacques; de Saussure, Philippe; Mottet, Christian; Seibold, Frank; Rogler, Gerhard; Sagmeister, Markus; Felley, Christian; Michetti, Pierre; Froehlich, Florian; Swiss IBD Cohort Study Group, The (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European journal of gastroenterology & hepatology, 22(11), pp. 1352-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/MEG.0b013e32833eaa8a
Full text not available from this repository. (Request a copy)Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD), but not all patients benefit from this therapy. We used data from the Swiss Inflammatory Bowel Disease Cohort Study and predefined appropriateness criteria to examine the appropriateness of use of infliximab (IFX) in CD patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology 04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Seibold, Frank Werner |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0954-691X |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:10 |
Last Modified: |
05 Dec 2022 14:01 |
Publisher DOI: |
10.1097/MEG.0b013e32833eaa8a |
PubMed ID: |
20964261 |
Web of Science ID: |
000282984600012 |
Additional Information: |
Christoph Müller (Institute of Pathology) is Member of the Swiss IBD Cohort Study Group |
URI: |
https://boris.unibe.ch/id/eprint/1488 (FactScience: 203171) |
Actions (login required)
 |
Edit item |